How much does Ransom Naturals Limited make?

Ransom Naturals Limited reported revenue of £5.9m and a loss of £1.5m in the year to 31 Dec 2025, according to its accounts filed at Companies House.

How many employees does Ransom Naturals Limited have?

Ransom Naturals Limited reported an average of 48 employees in the year to 31 Dec 2025.

Is Ransom Naturals Limited profitable?

No — Ransom Naturals Limited reported a loss of £1.5m in the year to 31 Dec 2025.

Company No. 07503850 · Incorporated 24 Jan 2011

Ransom Naturals Limited

Registered name: RANSOM NATURALS LIMITED

Part of Obg Pharmaceuticals Ltd group

Ransom Naturals Limited made £5.9m revenue and a £1.5m loss in the year to 31 Dec 2025. read from filing text

Ransom Naturals Limited’s revenue fell 22% to £5.9m in the year to 31 Dec 2025, with a loss of £1.5m and 48 employees. The company is classified under “manufacture of basic pharmaceutical products” and is based in Liverpool; we hold 4 years of its filed accounts.

Full P&L filedSection C · ManufacturingSIC 21100Manufacture of basic pharmaceutical products

Status: Active
Location: Liverpool, North West
Age: 15 yrs · since 2011
Type: Private Limited Company

Part of a group. The filing indicates this company sits within a group structure, so its results may depend on intra-group trading and it may be hard to replicate independently. From the filing: “The company is a wholly owned subsidiary of OBG Company Limited (previously OBG Pharmaceuticals Limited) which itself is a wholly owned subsidiary of the ultimate parent company, OBG Holding Limited. ”

Latest accounts · year to 31 Dec 2025

Key figures

Revenue

£5.9m

Growth ▼21.8%

Profit

−£1.5m

Growth —

Profit margin

−25.4%

Gross 33%

Employees

Change ▼5.9%

Profit / employee

−£31.4k

Revenue/employee £124k

Profitable streak

0yrs

Consecutive profitable years in our data

Badges are automated estimates derived from the filed figures — not statements of fact about the company.

4 filed years

Financial history

Multi-year financials, oldest to newest
Year to	31 Dec 2022	31 Dec 2023	31 Dec 2024	31 Dec 2025
Disclosure	No P&L	Full P&Lread from filing text	Full P&Lread from filing text	Full P&Lread from filing text
Profit & loss
Revenue (turnover)	—	£5.8m	£7.6m	£5.9m
Cost of sales	—	£3.4m	£4.6m	£4m
Gross profit	—	£2.4m	£3m	£2m
Profit before tax	—	−£803k	−£564k	−£1.8m
Profit after tax	—	−£875k	−£680k	−£1.5m
Profit (best available)	—	−£875k	−£680k	−£1.5m
Staff costs	—	£2.8m	£2.9m	£2.9m
Employees (average)	50	52	51	48
Ratios
Profit margin	—	−15.2%	−9%	−25.4%
Gross margin	—	41.7%	39.3%	33%
Revenue per employee	—	£111k	£149k	£124k
Profit per employee	—	−£16.8k	−£13.3k	−£31.4k
Growth (year on year)
Revenue growth	—	—	▲31.6%	▼21.8%
Headcount growth	—	▲4%	▼1.9%	▼5.9%
Balance sheet — indirect signals, not revenue
Cash at bank	£69.4k	£154k	£219k	£178k
Net assets	£2.9m	£2m	£1.3m	−£209k
Fixed assets	£2.9m	£3.3m	£3.7m	£3.5m
Current assets	£3m	£2.7m	£3.5m	£3m
Debtors	£1.2m	£888k	£1.3m	£1.3m
Deferred income	—	£454k	£189k	£253k
Source	FullAccounts · bulk data Sep 2024	FullAccounts · bulk data Sep 2024	FullAccounts · bulk data Sep 2025	FullAccounts · bulk data Sep 2026

Derived from the latest filing

How the business works

Profit margin: −25.4%; Profit ÷ revenue.
Gross margin: 33%; Gross profit ÷ revenue. High for software and services.
Revenue per employee: £124k; Revenue ÷ average employees.
Profit per employee: −£31.4k; Profit ÷ average employees.
Cash conversion: —; Cash generated from operations ÷ operating profit. Needs a cash-flow statement.
Fixed assets ÷ revenue: 59.3%; Capital intensity. Low = capital-light, cheaper to start.
Deferred income ÷ revenue: 4.3%; Customers paying upfront (subscriptions, deposits). Approximate when combined with accruals.
Debtors ÷ revenue: 21.6%; Money owed by customers. Low = customers pay quickly.

Indirect — not revenue

Balance-sheet signals

Year-on-year changes in filed balance-sheet items. They can hint at momentum (or investment) but are not revenue or profit and must not be read as such.

Net assets: ▼116%; Now −£209k
Cash at bank: ▼18%; Now £178k
Headcount: ▼6%; Now 48
Deferred income: ▲34%; Now £253k
Fixed assets: ▼6%; Now £3.5m

Deferred income is reported together with accruals in this filing (“accruals and deferred income”), so it is an approximate signal only.

Corporate ownership

Group structure

Ownership chain

Obg Pharmaceuticals Ltd (registered outside the UK register)ultimate parent75–100%
Ransom Naturals Limitedthis company

Bands show the share of ownership each company holds in the one below it.

From the Persons with Significant Control register (corporate controllers only).

Same industry, similar size

Similar profitable businesses

Industry benchmarks →

Sources

Companies House profile Filing history & original accounts

Latest figures from FullAccounts for the year to 31 Dec 2025 (profit −£1.5m), from the Companies House accounts bulk data published Sep 2026. Spotted an error? Request a correction.

Contains public sector information from Companies House licensed under the Open Government Licence v3.0. Data from Companies House, © Crown copyright. View the licence.